Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Fed Pract ; 36(1): 20-29, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30766414

ABSTRACT

NAFLD improves with 7% or greater weight loss.

2.
Hepatol Commun ; 2(9): 1136-1146, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30202826

ABSTRACT

Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti-cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti-CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death. Serologic evidence of prior HBV exposure is present in one in nine veterans in the Veterans Health Administration (VHA). In 2014, most (61%-73%) patients in the VHA who were receiving anti-CD20 Ab treatment underwent HBV testing, yet <20% of eligible patients received HBV antiviral prophylaxis. We aimed to prevent HBV reactivation by increasing HBV testing and antiviral treatment rates among anti-CD20 Ab recipients through prospective interventions. A multidisciplinary team of clinicians, pharmacists, and public health professionals developed comprehensive prevention systems, including national seminars/newsletters/websites; pharmacy criteria for HBV screening/treatment prior to anti-CD20 Ab use; changes to national formulary restrictions to expand HBV prophylaxis prescribing authority; Medication Use Evaluation Tracker to identify omissions; national e-mail alert to all VHA oncology providers detailing specific testing and HBV antiviral treatment needs; and a voluntary electronic medical record "order check" used at interested facilities (n = 11) to automatically assess pretreatment HBV testing and antiviral treatment and only generate a reminder to address deficiencies. Analysis of monthly data from June 2016 through September 2017 among anti-CD20 Ab recipients revealed pre-anti-CD20 Ab treatment HBV testing increased to 91%-96% and appropriate HBV antiviral prophylaxis to 76%-85% nationally following implementation of the intervention. Medical centers using the voluntary electronic medical record order check increased HBV testing rates to 93%-98% and HBV antiviral prophylaxis rates to 99%. Conclusion: Multimodal intervention systems to prevent HBV reactivation among VHA patients receiving anti-CD20 Ab therapies increased national rates of HBV testing to >90% and antiviral prophylaxis to >80%.

3.
Dig Dis Sci ; 63(10): 2813-2814, 2018 10.
Article in English | MEDLINE | ID: mdl-30043282

ABSTRACT

The original version of the article unfortunately contained errors in Table 3, Risk Factor column headings "Age > 50 (n = 115)," "Age > 50-64 (n = 154)," and "Age > 65 + (n = 60)."

4.
Dig Dis Sci ; 63(9): 2259-2266, 2018 09.
Article in English | MEDLINE | ID: mdl-29779083

ABSTRACT

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Severe NAFLD with advanced fibrosis results in substantial morbidity and mortality. Associated with metabolic syndrome, NAFLD is often initially clinically silent, yet intensive lifestyle intervention with 7% or greater weight loss can improve or resolve NAFLD. Using a Veterans Health Administration (VHA) liver biopsy cohort, we evaluated simple noninvasive fibrosis scoring systems to identify NAFLD with advanced fibrosis (or severe disease) to assist providers. METHODS: In our retrospective study of a national VHA sample of patients with biopsy-proven NAFLD or normal liver (2005-2015), we segregated patients by fibrosis stage (0-4). Non-NAFLD liver disease was excluded. We evaluated the diagnostic accuracy of the NAFLD fibrosis score (NFS), fibrosis-4 calculator (FIB-4), aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT ratio), AST-to-platelet ratio index (APRI), and body mass index, AST/ALT ratio, and diabetes (BARD) score by age groups. RESULTS: We included 329 patients with well-defined liver histology (296 NAFLD and 33 normal controls without fibrosis), in which 92 (28%) had advanced (stage 3-4) fibrosis. Across all age groups, NFS and FIB-4 best predicted advanced fibrosis (NFS with 0.676 threshold: AUROC 0.71-0.76, LR + 2.30-22.05, OR 6.00-39.58; FIB-4 with 2.67 threshold: AUROC of 0.62-0.80, LR + 4.70-27.45, OR 16.34-59.65). CONCLUSIONS: While NFS and FIB-4 scores exhibit good diagnostic accuracy, FIB-4 is optimal in identifying NAFLD advanced fibrosis in the VHA. Easily implemented as a point-of-care clinical test, FIB-4 can be useful in directing patients that are most likely to have advanced fibrosis to GI/hepatology consultation and follow-up.


Subject(s)
Decision Support Techniques , Liver Cirrhosis/diagnosis , Liver/pathology , Non-alcoholic Fatty Liver Disease/diagnosis , United States Department of Veterans Affairs , Veterans Health , Adolescent , Adult , Aged , Alanine Transaminase/blood , Area Under Curve , Aspartate Aminotransferases/blood , Biomarkers/blood , Biopsy , Body Mass Index , Clinical Enzyme Tests , Databases, Factual , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Female , Health Status , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/epidemiology , Liver Cirrhosis/pathology , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/epidemiology , Non-alcoholic Fatty Liver Disease/pathology , Platelet Count , Point-of-Care Testing , Predictive Value of Tests , Prevalence , Prognosis , ROC Curve , Reproducibility of Results , Retrospective Studies , Risk Factors , Severity of Illness Index , United States/epidemiology , Young Adult
5.
Contemp Clin Trials ; 58: 1-12, 2017 07.
Article in English | MEDLINE | ID: mdl-28445783

ABSTRACT

BACKGROUND: Rates of glycemic control remain suboptimal nationwide. Medication intensification for diabetes can have undesirable side effects (weight gain, hypoglycemia), which offset the benefits of glycemic control. A Shared Medical Appointment (SMA) intervention for diabetes that emphasizes weight management could improve glycemic outcomes and reduce weight while simultaneously lowering diabetes medication needs, resulting in less hypoglycemia and better quality of life. We describe the rationale and design for a study evaluating a novel SMA intervention for diabetes that primarily emphasizes low-carbohydrate diet-focused weight management. METHODS: Jump Starting Shared Medical Appointments for Diabetes with Weight Management (Jump Start) is a randomized, controlled trial that is allocating overweight Veterans (body mass index≥27kg/m2) with type 2 diabetes into two arms: 1) a traditional SMA group focusing on medication management and self-management counseling; or 2) an SMA group that combines low-carbohydrate diet-focused weight management (WM/SMA) with medication management. Hemoglobin A1c reduction at 48weeks is the primary outcome. Secondary outcomes include hypoglycemic events, diabetes medication use, weight, medication adherence, diabetes-related quality of life, and cost-effectiveness. We hypothesize that WM/SMA will be non-inferior to standard SMA for glycemic control, and will reduce hypoglycemia, diabetes medication use, and weight relative to standard SMA, while also improving quality of life and costs. CONCLUSIONS: Jump Start targets two common problems that are closely related but infrequently managed together: diabetes and obesity. By focusing on diet and weight loss as the primary means to control diabetes, this intervention may improve several meaningful patient-centered outcomes related to diabetes.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/therapy , Office Visits , Overweight/epidemiology , Overweight/therapy , Patient Education as Topic/organization & administration , Blood Glucose , Body Mass Index , Body Weights and Measures , Cost-Benefit Analysis , Diabetes Mellitus, Type 2/drug therapy , Diet, Carbohydrate-Restricted/methods , Glycated Hemoglobin , Humans , Hypoglycemic Agents/therapeutic use , Patient Education as Topic/economics , Quality of Life , Research Design , Self-Management/methods , Single-Blind Method , Veterans , Weight Loss , Weight Reduction Programs/organization & administration
6.
Appetite ; 83: 117-124, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25149197

ABSTRACT

Individuals undertaking a weight loss effort have a choice among proven dietary approaches. Factors contributing to choice of either a low-fat/low-calorie diet or a low-carbohydrate diet, two of the most studied and popular dietary approaches, are unknown. The current study used data from participants randomized to the 'choice' arm of a trial examining whether being able to choose a diet regimen yields higher weight loss than being randomly assigned to a diet. At study entry, participants attended a group session during which they were provided tailored feedback indicating which diet was most consistent with their food preferences using the Geiselman Food Preference Questionnaire (FPQ), information about both diets, and example meals for each diet. One week later, they indicated which diet they chose to follow during the 48-week study, with the option of switching diets after 12 weeks. Of 105 choice arm participants, 44 (42%) chose the low-fat/low-calorie diet and 61 (58%) chose the low-carbohydrate diet. In bivariate analyses, diet choice was not associated with age, race, sex, education, BMI, or diabetes (all p > 0.05). Low-carbohydrate diet choice was associated with baseline higher percent fat intake (p = 0.007), lower percent carbohydrate intake (p = 0.02), and food preferences consistent with a low-carbohydrate diet according to FPQ (p < 0.0001). In a multivariable logistic regression model, only FPQ diet preference was associated with diet choice (p = 0.001). Reported reasons for diet choice were generally similar for those choosing either diet; however, concerns about negative health effects of the unselected diet was rated as more influential among participants selecting the low-fat diet. Only three low-carbohydrate and two low-fat diet participants switched diets at 12 weeks. Results suggest that when provided a choice between two popular weight loss dietary approaches, an individual's selection is likely influenced by baseline dietary intake pattern, and especially by his or her dietary preferences. Research is needed to determine if congruency between food preferences and dietary approach is associated with weight loss.


Subject(s)
Caloric Restriction , Choice Behavior , Diet, Carbohydrate-Restricted , Diet, Fat-Restricted , Food Preferences , Obesity/diet therapy , Weight Loss , Adult , Aged , Behavior Therapy , Body Mass Index , Diet, Reducing , Dietary Carbohydrates/administration & dosage , Dietary Fats/administration & dosage , Energy Intake , Feeding Behavior , Female , Humans , Male , Middle Aged , Surveys and Questionnaires , Weight Reduction Programs
7.
J Psychosom Res ; 73(5): 351-5, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23062808

ABSTRACT

OBJECTIVE: To create and validate empirically derived questionnaires that measure non-gastrointestinal symptoms and disorders that co-exist with irritable bowel syndrome (IBS). METHODS: A systematic review of the world literature identified all non-GI symptoms and diagnoses known to have excess frequency in IBS patients. These data were used to create the Recent Physical Symptoms Questionnaire (RPSQ), which measures somatization (the psychological tendency to report multiple physical symptoms), and the Comorbid Medical Conditions Questionnaire (CMCQ). The psychometric properties of these questionnaires were assessed in two studies: 109 IBS patients in Study I; 286 IBS patients and 67 healthy controls in Study II. RESULTS: In Study I, the RPSQ and CMCQ showed high test-retest reliability (r=.88 and .95) and good internal consistency (Cronbach alphas: .86 and .70, respectively). In Study II, principal components analysis demonstrated that the RPSQ is a homogeneous somatization scale, but the CMCQ could be divided into 4 subscales: one for psychiatric disorders and 3 for different types of somatic disorders. Concurrent validity of the RPSQ was shown by strong correlations with the Cornell Medical Index (CMI) and the Brief Symptom Inventory-18 (BSI-18) somatization scales. The validity of CMCQ responses was not assessed. Discriminant validity was modest: the BSI-18 anxiety and depression scales were less strongly correlated with the RPSQ than the BSI-18 somatization scale. The RPSQ and CMCQ scores of IBS patients were significantly higher than the scores of healthy controls (P<.001). CONCLUSIONS: The RPSQ and CMCQ are psychometrically sound measures of somatization and medical comorbidities in IBS.


Subject(s)
Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/epidemiology , Somatoform Disorders/diagnosis , Somatoform Disorders/epidemiology , Adult , Comorbidity , Female , Humans , Male , Middle Aged , Psychometrics , Reproducibility of Results , Sensitivity and Specificity , Surveys and Questionnaires
8.
Am J Gastroenterol ; 107(2): 286-95, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22068664

ABSTRACT

OBJECTIVES: The objectives of this study were to determine how variable stool consistency is in patients with irritable bowel syndrome (IBS) and to assess the relationship between stool consistency and gastrointestinal symptoms. METHODS: Individuals with a physician diagnosis of IBS were recruited by advertisement. Enrollment questionnaires included the Rome III Diagnostic Questionnaire and IBS Symptom Severity Scale. Then, 185 patients meeting the Rome criteria for IBS rated the consistency (using the Bristol Stool Scale) of each bowel movement (BM) for 90 days and whether the BM was accompanied by pain, urgency, or soiling. Each night, they transferred BM ratings from a paper diary to an internet form and also reported the average daily intensity of abdominal pain, bloating, bowel habit dissatisfaction, and life interference of bowel symptoms. Only the longest sequence of consecutive days of diary data was used in the analysis (average of 73 days). RESULTS: Patients were 89% females with average age 36.6 years. Among the patients, 78% had both loose/watery and hard/lumpy stools; the average was three fluctuations between these extremes per month. The proportion of loose/watery stools correlated r=0.78 between the first and second months and the proportion of hard/lumpy stools correlated r=0.85 between months. Loose/watery stools were associated with more BM-related pain, urgency, and soiling than hard/lumpy or normal stools; however, IBS-C patients had significantly more BM-unrelated abdominal pain, bloating, dissatisfaction with bowel habits, and life interference than IBS-D patients. Questionnaires overestimated the frequency of abnormal stool consistency and gastrointestinal symptoms compared with diaries. CONCLUSIONS: Stool consistency varies greatly within individuals. However, stool patterns are stable within an individual from month to month. The paradoxical findings of greater symptom severity after individual loose/watery BMs vs. greater overall symptom severity in IBS-C implies different physiological mechanisms for symptoms in constipation compared with diarrhea. Daily symptom monitoring is more sensitive and reliable than a questionnaire.


Subject(s)
Constipation/physiopathology , Defecation/physiology , Diarrhea/physiopathology , Feces , Irritable Bowel Syndrome/physiopathology , Abdominal Pain/complications , Abdominal Pain/physiopathology , Adult , Aged , Constipation/complications , Diarrhea/complications , Female , Humans , Irritable Bowel Syndrome/complications , Male , Middle Aged , Surveys and Questionnaires
9.
Am J Gastroenterol ; 105(10): 2228-34, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20502449

ABSTRACT

OBJECTIVES: The Rome III classification system treats functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C) as distinct disorders, but this distinction appears artificial, and the same drugs are used to treat both. This study's hypothesis is that FC and IBS-C defined by Rome III are not distinct entities. METHODS: In all, 1,100 adults with a primary care visit for constipation and 1,700 age- and gender-matched controls from a health maintenance organization completed surveys 12 months apart; 66.2% returned the first questionnaire. Rome III criteria identified 231 with FC and 201 with IBS-C. The second survey was completed by 195 of the FC and 141 of the IBS-C cohorts. Both surveys assessed the severity of constipation and IBS, quality of life (QOL), and psychological distress. RESULTS: (i) Overlap: if the Rome III requirement that patients meeting criteria for IBS cannot be diagnosed with FC is suspended, 89.5% of IBS-C cases meet criteria for FC and 43.8% of FC patients fulfill criteria for IBS-C. (ii) No qualitative differences between FC and IBS-C: 44.8% of FC patients report abdominal pain, and paradoxically IBS-C patients have more constipation symptoms than FC. (iii) Switching between diagnoses: by 12 months, 1/3 of FC transition to IBS-C and 1/3 of IBS-C change to FC. CONCLUSIONS: Patients identified by Rome III criteria for FC and IBS-C are not distinct groups. Revisions to the Rome III criteria, possibly including incorporation of physiological tests of transit and pelvic floor function, are needed.


Subject(s)
Constipation/diagnosis , Irritable Bowel Syndrome/diagnosis , Adult , Aged , Constipation/classification , Diagnosis, Differential , Female , Humans , Irritable Bowel Syndrome/classification , Male , Middle Aged , Patient Selection , Prospective Studies , Quality of Life , Statistics, Nonparametric , Surveys and Questionnaires
10.
Am J Obstet Gynecol ; 202(5): 493.e1-6, 2010 May.
Article in English | MEDLINE | ID: mdl-20223447

ABSTRACT

OBJECTIVE: We sought to estimate the frequency of self-reported fecal incontinence (FI), identify what proportion of these patients have a diagnosis of FI in their medical record, and compare health care costs and utilization in patients with different severities of FI to those without FI. STUDY DESIGN: Patients in a health maintenance organization were eligible and 1707 completed a survey. Patients with self-reported FI were assessed for a diagnosis of FI in their medical record for the last 5 years. Health care costs and utilization were obtained from claims data. RESULTS: FI was reported by 36.2% of primary care patients, but only 2.7% of patients with FI had a medical diagnosis. FI adversely affected quality of life and severe FI was associated with 55% higher health care costs (including 77% higher gastrointestinal-related health care costs) compared to continent patients. CONCLUSION: Increased screening of FI is needed.


Subject(s)
Fecal Incontinence/epidemiology , Aged , Fecal Incontinence/diagnosis , Fecal Incontinence/economics , Female , Health Care Costs , Health Maintenance Organizations/statistics & numerical data , Humans , Male , Middle Aged , Prevalence , Primary Health Care , Quality of Life , Washington/epidemiology
11.
Am J Gastroenterol ; 103(10): 2550-61, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18684175

ABSTRACT

OBJECTIVES: Irritable bowel syndrome (IBS) patients show pain hypersensitivity and hypercontractility in response to colonic or rectal distention. Aims were to determine whether predominant bowel habits and IBS symptom severity are related to pain sensitivity, colon motility, or smooth muscle tone. METHODS: One hundred twenty-nine patients classified as IBS with diarrhea (IBS-D, N = 44), IBS with constipation (IBS-C, N = 29), mixed IBS (IBS-M, N = 45), and unspecified IBS (IBS-U, N = 11) based on stool consistency, and 30 healthy controls (HC) were studied. A manometric catheter containing a 600-mL capacity plastic bag was positioned in the descending colon. Pain threshold was assessed using a barostat. Motility was assessed for 10 min with the bag minimally inflated (individual operating pressure [IOP]), 10 min at 20 mmHg above the IOP, and for 15-min recovery following bag inflation. Motility was also recorded for 30 min following an 810-kcal meal. RESULTS: Compared with HC, IBS patients had lower pain thresholds (medians 30 vs 40 mmHg, P < 0.01), but IBS subtypes were not different. IBS symptom severity was correlated with pain thresholds (rho =-0.36, P < 0.001). During distention, the motility index (MI) was significantly higher in IBS compared with HC (909 +/- 73 vs 563 +/- 78, P < 0.01). Average barostat bag volume at baseline was higher (muscle tone lower) in HC compared with IBS-D and IBS-M but not compared with IBS-C. The baseline MI and bag volume differed between IBS-D and IBS-C and correlated with symptoms of abdominal distention and dissatisfaction with bowel movements. Pain thresholds and MI during distention were uncorrelated. CONCLUSIONS: Pain sensitivity and colon motility are independent factors contributing to IBS symptoms. Treatment may need to address both, and to be specific to predominant bowel habit.


Subject(s)
Abdominal Pain/diagnosis , Colon/physiopathology , Irritable Bowel Syndrome/complications , Peristalsis/physiology , Abdominal Pain/etiology , Abdominal Pain/physiopathology , Adult , Female , Follow-Up Studies , Humans , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/physiopathology , Male , Pain Measurement , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires
12.
BMC Complement Altern Med ; 8: 46, 2008 Jul 24.
Article in English | MEDLINE | ID: mdl-18652682

ABSTRACT

BACKGROUND: Functional Bowel Disorders (FBD) are chronic disorders that are difficult to treat and manage. Many patients and doctors are dissatisfied with the level of improvement in symptoms that can be achieved with standard medical care which may lead them to seek alternatives for care. There are currently no data on the types of Complementary and Alternative Medicine (CAM) used for FBDs other than Irritable Bowel Syndrome (IBS), or on the economic costs of CAM treatments. The aim of this study is to determine prevalence, types and costs of CAM in IBS, functional diarrhea, functional constipation, and functional abdominal pain. METHODS: 1012 Patients with FBD were recruited through a health care maintenance organization and followed for 6 months. Questionnaires were used to ascertain: Utilization and expenditures on CAM, symptom severity (IBS-SS), quality of life (IBS-QoL), psychological distress (BSI) and perceived treatment effectiveness. Costs for conventional medical care were extracted from administrative claims. RESULTS: CAM was used by 35% of patients, at a median yearly cost of $200. The most common CAM types were ginger, massage therapy and yoga. CAM use was associated with female gender, higher education, and anxiety. Satisfaction with physician care and perceived effectiveness of prescription medication were not associated with CAM use. Physician referral to a CAM provider was uncommon but the majority of patients receiving this recommendation followed their physician's advice. CONCLUSION: CAM is used by one-third of FBD patients. CAM use does not seem to be driven by dissatisfaction with conventional care. Physicians should discuss CAM use and effectiveness with their patients and refer patients if appropriate.


Subject(s)
Complementary Therapies/economics , Complementary Therapies/statistics & numerical data , Health Maintenance Organizations/statistics & numerical data , Irritable Bowel Syndrome/economics , Irritable Bowel Syndrome/therapy , Patient Satisfaction/statistics & numerical data , Abdominal Pain/economics , Abdominal Pain/therapy , Adult , Constipation/economics , Constipation/therapy , Cost-Benefit Analysis , Delivery of Health Care, Integrated/economics , Delivery of Health Care, Integrated/statistics & numerical data , Diarrhea/economics , Diarrhea/therapy , Female , Zingiber officinale , Humans , Male , Massage/economics , Massage/statistics & numerical data , Middle Aged , Patient Satisfaction/economics , Phytotherapy/economics , Phytotherapy/statistics & numerical data , Professional-Patient Relations , Prospective Studies , Surveys and Questionnaires , United States , Yoga
13.
Int J Clin Exp Hypn ; 54(1): 85-99, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16316885

ABSTRACT

Hypnosis treatment often improves irritable bowel syndrome (IBS), but the costs and reliance on specialized therapists limit its availability. A 3-month home-treatment version of a scripted hypnosis protocol previously shown to improve all central IBS symptoms was completed by 19 IBS patients. Outcomes were compared to those of 57 matched IBS patients from a separate study receiving only standard medical care. Ten of the hypnosis subjects (53%) responded to treatment by 3-month follow-up (response defined as more than 50% reduction in IBS severity) vs. 15 (26%) of controls. Hypnosis subjects improved more in quality of life scores compared to controls. Anxiety predicted poor treatment response. Hypnosis responders remained improved at 6-month follow-up. Although response rate was lower than previously observed in therapist-delivered treatment, hypnosis home treatment may double the proportion of IBS patients improving significantly across 6 months.


Subject(s)
Autogenic Training , Home Care Services , Hypnosis/methods , Irritable Bowel Syndrome/therapy , Adult , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/psychology , Male , Middle Aged , Pilot Projects , Quality of Life/psychology
14.
Dig Dis Sci ; 49(7-8): 1236-43, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15387352

ABSTRACT

The aim was to assess the roles of gut hormones and immune dysfunction in irritable bowel. In Study I, rectal mucosal samples examined blindly showed no histological evidence of inflammation in 16 irritable bowel patients compared to 17 healthy controls. The proinflammatory mediators interleukin-1beta and prostaglandin E2 also failed to show evidence of inflammation. Vasoactive intestinal peptide was elevated in irritable bowel (P = 0.01), but substance P, calcitonin gene-related peptide, and somatostatin levels were similar to control values. In Study II, 30 irritable bowel patients had elevated (P = 0.002) plasma concentrations of vasoactive intestinal peptide compared to 30 controls, and peptide levels were unrelated to whether the patient's predominant bowel habit was constipation, diarrhea, or both in alternation. In conclusion, no evidence of inflammation was detected in irritable bowel patients, but elevated vasoactive intestinal peptide concentrations were observed in both studies and might represent a potential diagnostic tool for irritable bowel syndrome.


Subject(s)
Irritable Bowel Syndrome/blood , Vasoactive Intestinal Peptide/blood , Adult , Blotting, Western , Calcitonin Gene-Related Peptide/analysis , Dinoprostone/blood , Female , Humans , Immunoassay , Interleukin-1/blood , Intestinal Mucosa/chemistry , Male , Somatostatin/analysis , Substance P/analysis
15.
Dig Dis Sci ; 47(11): 2605-14, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12452403

ABSTRACT

Hypnosis improves irritable bowel syndrome (IBS), but the mechanism is unknown. Possible physiological and psychological mechanisms were investigated in two studies. Patients with severe irritable bowel syndrome received seven biweekly hypnosis sessions and used hypnosis audiotapes at home. Rectal pain thresholds and smooth muscle tone were measured with a barostat before and after treatment in 18 patients (study I), and treatment changes in heart rate, blood pressure, skin conductance, finger temperature, and forehead electromyographic activity were assessed in 24 patients (study II). Somatization, anxiety, and depression were also measured. All central IBS symptoms improved substantially from treatment in both studies. Rectal pain thresholds, rectal smooth muscle tone, and autonomic functioning (except sweat gland reactivity) were unaffected by hypnosis treatment. However, somatization and psychological distress showed large decreases. In conclusion, hypnosis improves IBS symptoms through reductions in psychological distress and somatization. Improvements were unrelated to changes in the physiological parameters measured.


Subject(s)
Colonic Diseases, Functional/therapy , Hypnosis , Abdominal Pain/therapy , Adult , Colonic Diseases, Functional/physiopathology , Colonic Diseases, Functional/psychology , Female , Humans , Male , Psychometrics , Stress, Psychological/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...